Becker's Healthcare May 24, 2024
Cameron Cortigiano

An advisory committee to the FDA voted that a blood test that screens for colon and rectal cancers was safe, according to a May 23 report by The New York Times.

The test, designed by Guardant Health, offers an alternative to a colonoscopy or self-administered fecal test for individuals with an average risk for colon and rectal cancers.

However, blood tests are not as effective as colonoscopies at...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: FDA, Govt Agencies, Patient / Consumer, Provider
Opinion: STAT+: The biggest challenge facing the FDA’s new Rare Disease Innovation Hub
STAT+: For this cancer-focused digital health startup, an FDA rejection meant the end of the road
Legacy medical devices keep regulators up at night
How the FDA sees its role vis-à-vis AI in healthcare
FDA, Health Canada give sneak peek into future AI regs

Share This Article